首页> 美国卫生研究院文献>Disease Markers >Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Activity in Human Glioma Samples Predicts Tumor Presence and Clinical Prognosis
【2h】

Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Activity in Human Glioma Samples Predicts Tumor Presence and Clinical Prognosis

机译:胶质瘤样品中基质金属蛋白酶9 /中性粒细胞明胶酶相关的脂蛋白复合物活性可预测肿瘤的存在和临床预后

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Matrix metalloproteinase-9eutrophil gelatinase-associated lipocalin (MMP-9/NGAL) complex activity is elevated in brain tumors and may serve as a molecular marker for brain tumors. However, the relationship between MMP-9/NGAL activity in brain tumors and patient prognosis and treatment response remains unclear. Here, we compared the clinical characteristics of glioma patients with the MMP-9/NGAL activity measured in their respective tumor and urine samples. Using gelatin zymography assays, we found that MMP-9/NGAL activity was significantly increased in tumor tissues (TT) and preoperative urine samples (Preop-1d urine). Activity was reduced by seven days after surgery (Postop-1w urine) and elevated again in cases of tumor recurrence. The MMP-9/NGAL status correlated well with MRI-based tumor assessments. These findings suggest that MMP-9/NGAL activity could be a novel marker to detect gliomas and predict the clinical outcome of patients.
机译:基质金属蛋白酶9 /中性粒细胞明胶酶相关的脂钙素(MMP-9 / NGAL)复合物的活性在脑肿瘤中升高,并可作为脑肿瘤的分子标记。然而,脑肿瘤中MMP-9 / NGAL活性与患者预后和治疗反应之间的关系仍不清楚。在这里,我们将神经胶质瘤患者的临床特征与在各自的肿瘤和尿液样本中测得的MMP-9 / NGAL活性进行了比较。使用明胶酶谱测定法,我们发现肿瘤组织(TT)和术前尿液样品(Preop-1d尿液)中的MMP-9 / NGAL活性显着增加。手术后7天(P​​ostop-1w尿液)活动减少,并且在肿瘤复发的情况下再次增加。 MMP-9 / NGAL状态与基于MRI的肿瘤评估密切相关。这些发现表明,MMP-9 / NGAL活性可能是检测神经胶质瘤和预测患者临床结局的新标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号